Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03263481 · ClinicalTrials.gov registry record · NA
Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT03263481: Completed NA study, sponsored by Indiana University.
NCT03263481 is a NA study that has completed, run by Indiana University. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03263481, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The aim is to evaluate the peak secretory flow rates and bicarbonate concentrations as determined by a 30 minute intraductal secretin stimulation test in patients with a low likelihood of pancreatic pathology and to compare these data to those obtained from our historical patients with suspected chronic pancreatitis. These will be patients in which inadvertent pancreatic cannulation occurs during therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for biliary indications . All study subjects will receive a 5 day follow-up phone call. Enrollment goal is 36 subjects.
Primary Outcome
Volume of pancreatic juices will be collected
Interventions
- PROCEDURE Intraductal secretin test (IDST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2023-09-01 |
| Phase | NA |
What the finished NCT03263481 record still lists
NCT03263481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Intraductal secretin test (IDST) is the first listed.
NCT03263481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03263481 about?
NCT03263481 is a clinical study titled "Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?". The aim is to evaluate the peak secretory flow rates and bicarbonate concentrations as determined by a 30 minute intraductal secretin stimulation test in patients with a low likelihood of pancreatic pathology and to compare these data to those obtained from our historical patients with suspected chr...
What is the current status of trial NCT03263481?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2017-09-01. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT03263481?
The interventions under investigation include: Intraductal secretin test (IDST) (PROCEDURE).
Who is sponsoring clinical trial NCT03263481?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03263481's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI